Arthneeti

Akums Drugs & Pharmaceuticals Q1 FY27 Share Price & Earnings Call Analysis

₹741.05+2.54% today
Market cap
₹11,671 Cr
P/E
38.27
ROE
8.45%
PEG
1.34
Price to sales
2.58
Debt to equity
0.05
52W high / low
₹823 / ₹414
Sales growth (5Y)
9.87%
EBITDA margin
12.61%
Net profit margin
6.19%
Promoter holding
75.26%
Sales (last year)
₹4,502 Cr

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

Guidance scorecard · Q1 FY27 call

What Akums Drugs & Pharmaceuticals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#49of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsUp 0–2%CapexPlannedFundraisingWhat management saidOrder bookRising

RevenueQ1 FY27 call

10–20%
  • The company expects double-digit volume growth for the domestic branded formulation (Akumentis) business in the coming quarters and years, driven by new product launches and expansion into adjacent geographies with increased field force.
  • CDMO segment showed healthy volume growth of over 18% year-on-year; Q2 volume growth also looks strong at high teens, with positive momentum expected to continue.
  • Overall volume growth in the industry is expected to sustain, with the company positioned to outperform market growth.
  • New manufacturing capacities (e.g., in oral tablets and a new facility in Baddi) coming online by year-end are expected to support volume growth.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Up 0–2%

See what Akums Drugs & Pharmaceuticals Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Akums is in the process of setting up one more oral manufacturing facility in Baddi, expected to go live by the end of FY27, which will significantly boost oral manufacturing capabilities.
  • The capex for this new facility is still under discussion and will be updated once finalized.
  • The company has INR1,600 crores of cash on the balance sheet, mostly parked in fixed deposits with nationalized banks, with no debt.
  • Akums is open to acquisitions that are value-accretive and strategically rational to the group, indicating potential future inorganic investments.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Akums Drugs & Pharmaceuticals Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

Rising
  • Advanced stages of agreement for supplying over 100 products to the Zambian government, expected to generate around $25 million revenue in H2 FY27.
  • European business expected to kickstart in FY28, contributing positively to revenue and margins.
  • Sustained volume growth in CDMO and international markets with new capacity additions planned.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Akums Drugs & Pharmaceuticals Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Akums Drugs & Pharmaceuticals Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Akums Drugs & Pharmaceuticals Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Akums Drugs & Pharmaceuticals Ltd

Quarterly Results

Quarter-by-quarter operating performance

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +9701,1811,0839441,0191,0331,0101,0561,0241,0181,1601,158
Expenses +1,0951,0299899418919128899628959231,0131,006
Operating Profit-1251529331281211219412994147152
OPM %-13%13%9%0%13%12%12%9%13%9%13%13%
Other Income +8-211010717192627321634
Interest1214121213125523232424
Depreciation303032343435454037384040
Profit before tax-1598759-33879291759666100121
Tax %18%62%-229%20%30%27%27%-99%32%35%32%33%
Net Profit +-18733195-3961676615065436881
EPS in Rs-13.162.2213.54-2.894.084.144.149.384.032.594.215.38

Financials of Akums Drugs & Pharmaceuticals Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +1,4641,6512,4142,7233,6723,6554,1784,1184,359
Expenses +1,3401,5072,2402,4853,7613,3614,0553,6543,837
Operating Profit124144174238-89294123465522
OPM %8%9%7%9%-2%8%3%11%12%
Other Income +662611715869109
Interest23222071746513594
Depreciation3138677095113126153155
Profit before tax7789114172-193150-45345382
Tax %51%50%62%28%30%35%-102%0%33%
Net Profit +436144123-251981344256
EPS in Rs366.55523.23335.61943.49-35.306.63-0.2821.4916.21
Dividend Payout %0%0%0%0%0%0%0%0%18%

Financials of Akums Drugs & Pharmaceuticals Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital11111429293131
Reserves4936287218846086896813,0163,283
Borrowings +25521317513039561956588157
Other Liabilities +2933181,1401,1372,0331,9052,2299601,976
Total Liabilities1,0421,1612,0372,1523,0503,2413,5044,0955,447
Fixed Assets +4445016459041,0211,0971,1911,3971,457
CWIP011571731103195163177
Investments01862000000
Other Assets +5986321,3291,2121,9982,0412,1182,5353,814
Total Assets1,0421,1612,0372,1523,0503,2413,5044,0955,447

Financials of Akums Drugs & Pharmaceuticals Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +728928131321774984651,181
Cash from Investing Activity +-150-123-190-109-235-305-331-548-930
Cash from Financing Activity +6637233-91236125-1087334
Net Cash Flow-11471-7033-459-10285
Free Cash Flow-78-34-3449-224-110212201958
CFO/OP72%98%44%74%-98%93%455%118%243%

Financials of Akums Drugs & Pharmaceuticals Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days685788718884736867
Inventory Days114115999311211790102110
Days Payable6760105749291769687
Cash Conversion Cycle1151128290109111877489
Working Capital Days787355664946407166
ROCE %14%20%-16%22%2%16%15%

Guidance history

How Akums Drugs & Pharmaceuticals Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%Up 0–2%Planned—Rising
Q4 FY26 call →10–20%FlatPlannedPlannedRising
Q3 FY26 call →10–20%FlatPlanned—Rising
Q2 FY26 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

42out of 100

Momentum score · price trend

42 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+58.7%87%
Last 6 months+35.4%83%
Last 3 months+12.2%81%

The price is 30.5% below its all-time high of ₹1,066.65 (16 Aug 2024). Stocks more than 20% below their peak have their score halved, so 84 became 42.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Akums Drugs & Pharmaceuticals Ltd: 0.4 × 87 + 0.4 × 83 + 0.2 × 81 = 84, halved to 42 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Akums Drugs & Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd